Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.
Indian drugmaker Glenmark Pharma has agreed to sell 75% of the shares in its subsidiary Glenmark Life Sciences (GLS) to detergent manufacturer Nirma for 56.515 million Indian rupees (about €639.000).
For Siegfried, sustainability is much more than a phrase with a green coating. The term, which encompasses social and economic criteria in addition to ecological aspects, is one of five central corporate values. One of the biggest levers for reducing energy and resource consumption in the pharma supply chain lies in the efficient production of active ingredients and pharmaceuticals. The company therefore works consistently on optimizing its processes.
After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.
The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.
The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability.
There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only count those that have been operating and thriving under the same name for a century and a half, the number boils down significantly.
Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.
German chemical group Wacker has acquired 100% of ADL Biopharma from private equity investor Kartesia for a price said to exceed €100 million. It now owns the entire 150,000 m2 production site in the northern Spanish city of Léon with fermentation capacity of just under 3,000 cbm (gross volume).
Rotterdam-based speciality chemicals distributor IMCD kicked off the month of May agreeing a major distribution partnership and two outright acquisitions.
India-headquartered drugmaker Glenmark is said to be taking another look at selling a majority stake in its business with active pharmaceutical ingredients (APIs), which is wrapped up in subsidiary Glenmark Life Sciences.
Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs now account for 25% of all drugs produced globally, with some analysts projecting that it will reach a value of $40 billion by 2027.
Under US president Joe Biden, the Department of Justice has been moving energetically of late to uncover and prosecute offenses that might otherwise have been swept under heavy rugs, including Covid-related API manufacturing contracts won under unclear circumstances.
Macfarlan Smith, a UK-based unit of US API maker Veranova, formerly known as Johnson Matthey Health, has completed a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities in Edinburgh, Scotland.
Given the challenges the pharmaceutical industry is facing – secure material supply, reduce operation cost and increase flexibility, enhance sustainability and safety, innovate and reduce time-to-market – the sector is poised for a breakthrough of flow chemistry.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd.
US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.
Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished dosage forms of amoxicillin and other key penicillin products.
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
Italian API producer Olon has announced plans to install a new high-containment production line at its site in Mahad, India.
Financed in part by the French government’s France Relance plan, Novasep‐PharmaZell is investing €7.3 million in production of active pharmaceuticals (APIs) at its Mourenx, France, site.
WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a focal point.
South Korean CDMO SK Pharmteco (SKTP) said it will spend $35 million on the initial phase of a planned expansion at the Dublin, Ireland, API site the conglomerate acquired from Bristol Myers Squibb in 2017. Prior to that, SK had been a BMS supplier for around a decade.
Major API supplier Olon is establishing a €10 million central R&D hub at its headquarters site in Roadano, near Milan. The Italian company said the facility paves the way for a further major expansion and diversification of its expertise in active pharmaceutical ingredients supplied to the CDMO and generics markets.
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Centrient Pharmaceuticals has started its expanded production of statins at its manufacturing plant for active pharmaceutical ingredients (APIs) in Toansa, India. With the start-up of its second unit at the site, the Dutch company said it has doubled capacity for Atorvastatin and Rosuvastatin, meeting the increased demand for its sustainably produced portfolio.
US-based CDMO Regis Technologies has completed a major expansion of its laboratory facilities for development of active pharmaceutical ingredients (APIs) at its site in Morton Grove, Illinois. The project, kicked off two years ago, doubles the company’s capacity to take on new development projects.
Sean Diver, president of DCAT speaks about the pharmaceutical industry’s role during the Covid-19 pandemic, trends in drug manufacturing, and key issues for the EU pharmaceutical industry.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable targets for oncology and other areas.
Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
